Matthew Murray, MD
Internal Medicine · Gulfport, MSNPI 1104238153
Payments from drug & device makers
Across 139 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$562
- GSK$348
- Averitas Pharma Inc.$290
- Novo Nordisk$248
- Lilly USA, LLC$172
- Bayer$168
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,897100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $562 |
| GSK | 26 | $348 |
| Averitas Pharma Inc. | 4 | $290 |
| Novo Nordisk | 15 | $248 |
| Lilly USA, LLC | 10 | $172 |
| Bayer | 9 | $168 |
| Pfizer | 7 | $141 |
| Johnson & Johnson | 6 | $129 |
| Sumitomo Pharma America, Inc. | 6 | $125 |
| Inspire Medical Systems, Inc. | 1 | $122 |
| Exact Sciences | 5 | $82 |
| Amgen | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 3 | $51 |
| AbbVie(2 entities) | 3 | $49 |
| Boehringer Ingelheim | 3 | $47 |
| Novartis | 2 | $45 |
| Renalytix AI, Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
| Medtronic | 1 | $21 |
| Merck | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,897 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 113 | $136,089 |
| FarxigaDapagliflozin Propanediol | 113 | $119,199 |
| JanuviaSitagliptin Phosphate | 76 | $77,298 |
| EliquisApixaban | 56 | $59,343 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $40,876 |
| MounjaroTirzepatide | 28 | $30,818 |
| OzempicSemaglutide | 20 | $23,178 |
| TrulicityDulaglutide | 21 | $22,192 |
| EntrestoSacubitril/Valsartan | 11 | $14,810 |
| DapagliflozinDapagliflozin Propanediol | 13 | $7,794 |
| Rosuvastatin Calcium | 347 | $3,758 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $2,983 |
| Metoprolol Succinate | 206 | $2,836 |
| Metformin Hcl ErMetformin Hcl | 289 | $2,655 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $47 | $136,089113 claims |
| AstraZenecaFarxiga, Symbicort | $562 | $122,181128 claims |
| MerckJanuvia | $21 | $77,29876 claims |
| PfizerEliquis | $141 | $59,34356 claims |
| Lilly USA, LLCMounjaro, Trulicity | $172 | $53,01049 claims |
| GSKTrelegy Ellipta | $348 | $40,87661 claims |
| Novo NordiskOzempic | $248 | $23,17820 claims |
| NovartisEntresto | $45 | $14,81011 claims |
| AbbVieSynthroid | $49 | $1,10215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Gulfport
- David PendleyGulfport$336K
- Mousa MaaloufGulfport$14K
- David LarosaGulfport$14K
- Phillip ComptonGulfport$10K
- Lynn LeatherwoodGulfport$10K
- Jay SegarraGulfport$9K
- Boyd BenefieldGulfport$7K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.